Atossa Therapeutics (NASDAQ: ATOS)
Atossa Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Atossa Therapeutics Company Info
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
News & Analysis
Can Atossa Therapeutics Stock Keep Climbing?
Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.
Why Atossa Therapeutics Stock Is Jumping Today
There are two likely drivers behind the biotech's share price surge.
Why Atossa Therapeutics Stock Is Tumbling Today
The sell-off resulted from the company's announcement of phase 2 data for experimental breast cancer drug endoxifen.
Why Atossa Therapeutics Blasted 30% Higher on Monday
The company might announce some extremely good news later this week.
Why Atossa Therapeutics Soared 20% Higher Today
An analyst tracking the stock gets even more bullish on its prospects.
Why Atossa Therapeutics Stock Soared Today
Investors are excited about the potential of the biotech's experimental breast cancer treatment.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.